Is rituximab one for all ages and each sex?

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)602-603
Number of pages2
JournalBlood
Volume123
Issue number5
DOIs
StatePublished - Jan 30 2014

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this